"If a drug provides significant value when treating one type of cancer, but very little value when treating a different kind of cancer, it makes no sense to pay the same amount for that drug."
— Express Scripts spokesperson David Whitrap told AIS's Drug Benefit News for a story on "differential pricing" the PBM is exploring with drugmakers.
No comments:
Post a Comment